Rollins School of Public Health
Atlanta, Georgia, 30322, United States
Location status: Recruiting
NCT Number: NCT07165808
The goal of this study is to assess the effects of nicotine concentration and its interplay with pH on sensory experience, product appeal, and abuse liability of NPs among young adults NP users.
Primary objective is to assess the effect of variation in nicotine concentration in nicotine pouches (NPs) and its interaction effect with pH level on three proximal outcomes of relevance to regulation: (1) sensory experience, (2) product appeal, and (3) abuse liability of NPs.
Interested in participating?
Request Info21 year–35 year
All sexes
Interventional
Not applicable
Atlanta, Georgia, 30322, United States
Location status: Recruiting
Oral nicotine pouches (NPs) are a rapidly growing segment of nicotine products regulated by the U.S. Food and Drug Administration (FDA). These microfiber pouches contain nicotine but no tobacco leaf, and they dissolve in the mouth without requiring spitting. Between late 2019 and early 2022, NP sales surged from 126 million to 808 million units. Their sleek packaging, concealability, and "tobacco-free" claims have made them particularly appealing to young adults, with recent studies showing that over 10% of young adults reported using NPs in the past 30 days. However, this popularity raises health concerns. NPs deliver nicotine efficiently through buccal absorption, leading to rapid increases in blood nicotine levels, which may contribute to oral toxicity, cardiovascular effects, and nicotine dependence. These factors also elevate the abuse liability of NPs-defined as the likelihood of non-medical use leading to harmful consequences.
The FDA has the authority to impose stricter regulations on products with characteristics that enhance appeal and sensory experience, especially among youth. For instance, the agency has proposed banning menthol cigarettes due to their ability to mask irritation and encourage deeper inhalation of nicotine. Similar regulatory scrutiny is now being applied to emerging products like NPs. One key factor influencing product appeal is nicotine formulation. Free-base nicotine, commonly used in non-combustible products like e-cigarettes (ECs), has aversive effects such as bitterness and airway irritation, especially at high concentrations. To counter this, manufacturers began adding organic acids to convert nicotine into a protonated salt, lowering the product's pH and improving its palatability. This shift not only enhances the sensory experience but also increases the abuse liability of high-nicotine products. Evidence suggests that regulating acid additives or setting minimum pH levels could reduce the appeal of these products. Since NPs also use acid additives to lower pH, they share similar characteristics with ECs that attract young users, underscoring the need for targeted regulatory action.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nicotine pouch: 3-4 mg
Nicotine pouch: 6-8 mg
Nicotine pouch with low pH level [<8.5]
Nicotine pouch with high pH level [>8.5]
Time frame: Visit 1, Visit 2, Visit 3, Visit 4 (all visits within 2-4 weeks)
Total amount of time with Nicotine Pouches in mouth (excluding periods in between NPs after disposal)
Time frame: Visit 1, Visit 2, Visit 3, Visit 4 (all visits within 2-4 weeks)
Total number of Nicotine Pouches used (i.e., larger number and longer time with Nicotine Pouches, higher abuse ability.
Time frame: Visit 1, Visit 2, Visit 3, Visit 4 (all visits within 2-4 weeks)
During the session, participants will also repeatedly (every 30 min) complete the subjective effects measures of abuse liability of NP (using VAS), which will be developed based on the Drug Effects Questionnaire (DEQ). A modified version of the DEQ will be used to rate acute responses to the NP on the Visual Analogue Scale (range, 0-100).
Items assess liking/wanting (e.g., "I enjoy nicotine buzz," "I feel good effects from the NP," "I want more," "I feel the NP strength," and "I like the NP effect").
Time frame: Visit 1, Visit 2, Visit 3, Visit 4 (all visits within 2-4 weeks)
Modified Cigarette Evaluation Questionnaire will also be used to measure domains of subjective reinforcing effects (product satisfaction, psychological reward; e.g., "NP is satisfying" on a 7-point scale (0-7).
Time frame: Visit 1, Visit 2, Visit 3, Visit 4 (all visits within 2-4 weeks)
After each administration, participants will use visual analogue scales (VAS, 0-100 range) to rate the product they just used: (1) "How much did you like the product?" (liking); (2) "How much did you dislike the product?" (disliking); and (3) "Would you use the product again?" (use again). A composite appeal score will also be calculated by averaging the 3 appeal ratings (Cronbach's α will be estimated to assess scale reliability; disliking will be reverse-scored).
Time frame: Visit 1, Visit 2, Visit 3, Visit 4 (all visits within 2-4 weeks)
Participants will answer following sensory quality questions: (1) "How sweet was the product?"; (2) smooth?; (3) bitter?; and (4) harsh? (VAS 0-100, "Not at all" to "Extremely". Burning and tingling sensation will be measured at each trial.
Time frame: past 30-day
Information will be collected on past 30-day number of days used nicotine pouches (NPs)
Time frame: past 30-day
Number of Nicotine product used per day
Time frame: past 30-day
Amount of time with Nicotine product in mouth per episode
Time frame: past 30-day
Data on brand names of NPs will be collected
Time frame: past 30-day
Number of e- cigarettes used in past 30 days.
Time frame: past 30-day
Number of tobacco products used in last 30 days
Time frame: Baseline
Test strips that provide a semiquantitative index of salivary cotinine will be collected to provide descriptive data on nicotine exposure.
Contact information is provided by the study sponsor or research team.
Emory University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07298902
Chemically-Induced Disorders, Mental Disorders
Houston, Texas, United States
View Trial DetailsNCT06803706
Alcohol Use Disorder (AUD), Alcohol-Related Disorders
Fehring, Austria
View Trial DetailsNCT07059377
Chemically-Induced Disorders, Diabetes Mellitus
Ottawa, Ontario, Canada
View Trial DetailsNCT06582888
Chemically-Induced Disorders, Craving
San Diego, California, United States
View Trial Details